MARKET

ABVC

ABVC

Abvc Biopharma Inc
NASDAQ
1.220
+0.020
+1.67%
Opening 11:19 03/28 EDT
OPEN
1.170
PREV CLOSE
1.200
HIGH
1.230
LOW
1.160
VOLUME
223.16K
TURNOVER
0
52 WEEK HIGH
9.60
52 WEEK LOW
0.6739
MARKET CAP
12.88M
P/E (TTM)
-0.5030
1D
5D
1M
3M
1Y
5Y
VERI, CHEK and MESO are among pre market gainers
VERI, CHEK and MESO are among pre market gainers. Mesoblast (MESO) and Cazoo Group (CZOO) are among the biggest pre market losers. Krispy Kreme and AirNet Technology are also on the move.
Seeking Alpha · 1d ago
Why ABVC BioPharma Stock Is Up Today
ABVC BioPharma, Inc. Has entered into a global licensing agreement with ForSeeCon Eye Corporation for the company’s ophthalmology pipeline. ABVC shares are trading higher Tuesday. The company does not pay a dividend, but ABVC has a few ways to return value to shareholders.
Benzinga · 2d ago
Abvc Biopharma Inc: Current report
Press release · 2d ago
NeuBase Therapeutics, ABVC BioPharma, Stoke Therapeutics among healthcare movers
NeuBase Therapeutics, ABVC BioPharma, Stoke Therapeutic among healthcare movers. S&P 500 Health Care Sector +0.2% to 1697.44. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 2d ago
ABVC Announces Global Licensing Deal With ForSeeCon Eye For Vitargus
NASDAQ · 2d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Stoke Therapeutics (NASDAQ:STOK) stock increased by 80.2% to $11.71 during Tuesday's pre-market session. The company's, Q4 earnings came out yesterday. OpGen shares moved upwards by 77.6% and Praxis Precision Medicine (PRAX) shares increased by 21.38%. ABVC BioPharma (ABVC) and Sutro Biopharma (STRO) were among the losers.
Benzinga · 2d ago
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
ABVC BioPharma, Inc. Has entered into a global licensing agreement with ForSeeCon Eye Corporation for the Company's ophthalmology pipeline. The company's medical device Vitargus is valued at $187M. The license will cover the company's clinical trial, registration, manufacturing, and distribution rights.
Barchart · 2d ago
Weekly Report: what happened at ABVC last week (0318-0322)?
Weekly Report · 3d ago
More
About ABVC
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of drugs and medical devices derived from plants. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, ABV-1703 and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1702 is used to treat myelodysplastic syndrome (MDS). ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. Its ABV-1519 is used for the treatment of non-small cell lung cancer.

Webull offers ABVC Biopharma Inc stock information, including NASDAQ: ABVC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABVC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABVC stock methods without spending real money on the virtual paper trading platform.